Company profile for Kala Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (lo...
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
100 Beaver St., Suite 201 Waltham, MA 02453
Telephone
Telephone
+1-781-996-5252
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2023/08/02/2716797/0/en/Kala-Pharmaceuticals-Announces-Name-Change-to-KALA-BIO.html

GLOBENEWSWIRE
02 Aug 2023

https://www.globenewswire.com/news-release/2023/07/19/2707717/0/en/Kala-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
19 Jul 2023

https://www.globenewswire.com/news-release/2023/06/23/2693902/0/en/Kala-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
23 Jun 2023

https://www.globenewswire.com/news-release/2023/06/02/2681101/0/en/Kala-Pharmaceuticals-to-Present-at-the-Jefferies-Healthcare-Conference.html

GLOBENEWSWIRE
02 Jun 2023

https://www.globenewswire.com/news-release/2023/05/09/2664373/0/en/Kala-Pharmaceuticals-Reports-First-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html

GLOBENEWSWIRE
09 May 2023

https://www.globenewswire.com/news-release/2023/04/12/2645285/0/en/Kala-Pharmaceuticals-Receives-FDA-Fast-Track-Designation-for-KPI-012-a-Human-MSC-S-Therapy-for-Persistent-Corneal-Epithelial-Defect.html

GLOBENEWSWIRE
12 Apr 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty